Sun Pharma Q2 Profit Falls 36% Due to Exceptional Charges; Revenue Rises 12%
Sun Pharmaceutical Industries reported a 36.2% year-on-year decline in consolidated net profit to approximately Rs 1,989 crore for Q2 FY27, impacted by one-time exceptional charges including Rs 346 crore in acquisition-related costs for its proposed Organon deal and a Rs 923 crore US litigation settlement. Despite this, revenue rose nearly 12% to Rs 16,199 crore, driven by growth in domestic formulations and emerging markets. Profit before exceptional items and tax increased 6.3%, with EBITDA up 4.8% and a margin of 29.3%. The Organon acquisition is expected to close in Q4 FY27.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (47/100). Lens Score 38/100.
Outlets measured: economictimes, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (42–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 30 Oct, 09:02 am. Other outlets followed.